top of page
Business Discussion
Health Economics and Outcomes Research (HEOR) services

Our HEOR services provide comprehensive solutions for the life science industry, enabling companies to unlock the value of their healthcare interventions. From economic evaluations to real-world evidence generation and market access support, our team combines scientific expertise with advanced analytics to optimize market access strategies and demonstrate the value of innovations.

Evidence synthesis 

PHARMAECONOMICA conducts state-of-the-art literature reviews and meta-analyses using the most rigorous methodologies, to ensure the reliability and reproducibility of the answers to your research questions.

High-quality literature reviews allow for an understanding of:

  • Disease patterns including etiology, definitions, and diagnosis

  • Epidemiologic, humanistic, and economic burden of the disease

  • Clinical Guidelines and patterns in clinical practice

  • Data and performance of the comparator treatments

  • Previous modeling exercises in the disease area

  • Inputs of the economic models on identification, measurement, and valuation of resource usage and utility estimates

We perform high-quality meta-analyses:

  • Pairwise meta-analysis (PMA): If the data from multiple trials are sufficiently homogenous, a pairwise meta-analysis can be performed to calculate pooled effect estimates. It involves groups of trials that compare the same two interventions directly (head-to-head)

  • Network meta-analysis (NMA): NMA combines trials with different treatments and comparators into a single framework and it permits to simultaneously accommodate direct and indirect comparisons. It also allows the estimation of the ranking and hierarchy of interventions.

  • Model-based meta-analysis (MBMA): MBMA  incorporates parametric pharmacology models (e.g., with dose and duration) and is able to integrate relevant pre-clinical, bio-marker, clinical safety, and efficacy data of competing treatment options in a certain disease area.

Benefits of our Evidence Synthesis Services

  • Product’s clinical differentiation

  • Prediction on how a new drug’s safety and efficacy profile might compare to the current SOC and other competitor drugs

  • Treatment comparisons even if no head-to-head trial available

  • Multi-treatment comparisons

  • Inform cost-effectiveness models (populate cost-effectiveness models)

  • Provide a ranking of the compared interventions for a particular outcome

  • Understanding of a drug’s dose-response relationship

  • Increase the probability of clinical trial success

  • MBMA has emerged as a methodology that quantifies clinical trial efficacy, tolerability, and safety information to enable strategic drug development decisions. It provides a quantitative framework for differentiation by allowing one to understand how a new compound will perform relative to existing relevant comparators and /or drugs in development

Health Economic Modeling

To estimate both costs and consequences of alternative courses of action, models synthesize information on a range of variables such as natural history, clinical efficacy, health-related quality of life, resource use, and costs and results of these analytical models are used to decide which interventions represent good value for money from the perspective of a particular decision maker.

We can help if  your Organization requires  a model to:

  • Understand disease patterns and unmet needs

  • Support strategic planning

  • Develop an economic evaluation

  • Demonstrate value to inform payer decisions

Our experts use state-of-the-art methods to develop high-quality decision analytic models:

  • Decision trees

  • Markov and other stochastic process models

  • Simulations (individual patient, discrete event, etc.)

  • Infectious disease models

  • Statistical analyses (survival analysis, multivariate regression, utility data analysis, etc.)

  • Probabilistic, bivariate, univariate, and structural sensitivity analysis

  • The expected value of perfect information

  • Multi-criteria decision analysis

  • Time-driven activity-based costing

Benefits of our Health Economic Modeling Services

  • Our high-quality cost-effectiveness models can be used for submission purposes to demonstrate value for money and gain national reimbursement recommendations in the UK, North America, Australia, Canada, Sweden, The Netherlands …..

  • A cost-effectiveness model also generates and demonstrates the economic value messages that will form a key component of the product value story to ensure the product’s market access and adoption.

  • We can develop a full range of economic models to estimate the cost of disease, incremental cost-effectiveness ratio, value-based pricing, budget impact, and expected value of perfect information.

  • Our experience covers spans across different therapeutic areas such as Cardiology, Oncology, Parenteral Nutrition, Epilepsy, Alzheimer, Infectious diseases (COVID, Ebola, Meningitis), etc. 

bottom of page